Literature DB >> 10839493

The pathology and management of subglottic cancer.

A Ferlito1, A Rinaldo.   

Abstract

Because there is still considerable controversy concerning the anatomical boundaries separating the three regions of the larynx, cancer of the subglottis remains difficult to manage. We have reviewed the numerous differences in the anatomical definitions used in the literature and the consequent differences in reported findings on the incidence of subglottic cancer and its classification. We have also summarized the pathology of subglottic malignant neoplastic lesions, their presenting symptoms and tendency for spread, and the use of imaging methods in its diagnosis. Suitable forms of treatment are discussed, as are considerations on prognosis.

Entities:  

Mesh:

Year:  2000        PMID: 10839493     DOI: 10.1007/s004050050217

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  4 in total

1.  Efficacy and toxicity of (chemo)radiotherapy for primary subglottic cancer.

Authors:  M Hata; T Taguchi; I Koike; G Nishimura; M Takahashi; M Komatsu; D Sano; K Odagiri; Y Minagawa; T Inoue
Journal:  Strahlenther Onkol       Date:  2012-11-18       Impact factor: 3.621

2.  Squamous cell carcinoma of the larynx with subglottic extension: is larynx preservation possible?

Authors:  A Levy; P Blanchard; S Temam; M-M Maison; F Janot; H Mirghani; F Bidault; J Guigay; A Lusinchi; J Bourhis; N Daly-Schveitzer; Y Tao
Journal:  Strahlenther Onkol       Date:  2014-03-04       Impact factor: 3.621

3.  Establishment of an immortalized human subglottic epithelial cell line.

Authors:  Jason Powell; Bernard Verdon; Janet A Wilson; A John Simpson; Jeffery Pearson; Chris Ward
Journal:  Laryngoscope       Date:  2019-01-08       Impact factor: 2.970

4.  Apatinib combined with concurrent chemoradiotherapy in patients with subglottic small cell carcinoma: a case report.

Authors:  Man Chen; Shuang Wu; Zelai He; Zenong Cheng; Shimiao Duan; Hao Jiang; Gengming Wang
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.